The global antibody drug
conjugates therapeutics market is expected to
witness significant growth due to current unmet medical need of some chronic
diseases such as cancer and immunological diseases, increasing prevalence of
such diseases, advancement in technologies and high demand for safe and
effective medication. The regulatory bodies are supporting the ADCs market by
providing designations and funding for speeding up the drug development
process. In April 2015, ImmunoGen, Inc. drug candidate Mirvetuximab
soravtansine got orphan drug designation by European Medicine Agency for the
treatment of ovarian cancer.
Explore Full Report Description
with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/adcs-therapeutics-market
The pipeline of ADCs
is rich with more than 200 drugs. The pharmaceutical companies are actively
involved in the research and development of drug for ADCs. Trastuzumab emtansineis, a Phase III clinical
trial drug candidate of Genentech, Inc., utilizes Tumor-Activated Prodrug
technology for the treatment of HER2-positive primary breast cancer. The
drug is already marketed under trade name Kadcyla for the treatment
of advanced human epidermal growth factor receptor 2 (HER2)-positive gastric
cancer and early HER2-positive breast cancer.
ADCs
are prepared by linking biologically active cytotoxic drugs to monoclonal
antibodies. An ADC comprises of a monoclonal antibody, cytotoxic drug and a
linker. ADCs have specific targeting ability of monoclonal antibody, and hence
these are capable of distinguishing healthy and diseased cells. Moreover, the
cancer-killing ability of cytotoxic drugs makes ADCs more effective against the
tumor cells. These characteristics increase the specificity and maximize the
efficacy of ADCs. The antibody component of ADCs recognizes the target antigen
and binds with it. After binding with the antigen, the cytotoxic component is
released inside the tumor cell, causing its death or degeneration. The
significant potential of ADCs in cancer treatment has attracted many
researchers and healthcare providers to develop new antibody therapeutics using
ADC technology.
A
large number of pharmaceutical companies are focusing towards research and
development of ADCs. However, certain factors such as unknown etiology, complex
pathophysiology and high treatment cost of cancer are expected to hamper the
growth of the global market during the forecast period.
Some of the key players operating in the
global market are ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Seattle
Genetics, Inc., F. Hoffmann-La Roche AG, BioAtla LLC, Philogen S.p.A., Viventia
Biotechnologies, Inc., Sutro Biopharma, Inc., Sorrento Therapeutics, Inc., and Immunobiochem
Corporation.
About P&S Market Research
P&S Market Research is a
market research company, which offers market research and consulting services
for various geographies around the globe. We provide market research reports,
industry forecasting reports, business intelligence, and research based consulting
services across different industry/business verticals.
As one of the top growing
market research agency, we’re keen upon providing market landscape and accurate
forecasting. Our analysts and consultants are proficient with business
intelligence and market analysis, through their interaction with leading
companies of the concerned domain. We help our clients with B2B market research
and assist them in identifying various windows of opportunity, and framing
informed and customized business expansion strategies in different regions.
Contact:
Abhishek
Executive – Client Partner
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.comWeb: https://www.psmarketresearch.com
No comments:
Post a Comment